Identifying CYP2C19 and CYP2D6 poor metabolizers from TDM data

Pharmacogenetic (PGx) analysis and therapeutic drug monitoring (TDM) are tools used for personalized dosing. While PGx enables pre-emptive dose predictions to hit target concentrations of specific drugs based on genetic information, TDM captures all sources of pharmacokinetic variability, but often needs steady-state conditions to provide reliable dose adjustments.Most laboratories perform either TDM or PGx. We used TDM data to predict critical drug-metabolizing phenotype, where poor metabolizers (PMs) of CYP2C19 or CYP2D6 probably represent the most important category.